成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ABT-199

ABT-199 Struktur
1257044-40-8
CAS-Nr.
1257044-40-8
Englisch Name:
ABT-199
Synonyma:
Venetoclax;Venclexta;ATB199;4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]ami;GDC-0199;Venetoclax (ABT-199, GDC-0199);2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy;4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide;4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide ABT-199 (GDC-0199);S8048
CBNumber:
CB62645962
Summenformel:
C45H50ClN7O7S
Molgewicht:
868.44
MOL-Datei:
1257044-40-8.mol

ABT-199 Eigenschaften

Schmelzpunkt:
>150°C (dec.)
Dichte
1.340±0.06 g/cm3(Predicted)
storage temp. 
-20°C Freezer
L?slichkeit
DMSO (Slightly)
Aggregatzustand
Yellow solid.
pka
4.09±0.10(Predicted)
Farbe
Light Yellow to Yellow
InChIKey
LQBVNQSMGBZMKD-UHFFFAOYSA-N
SMILES
C(NS(C1=CC=C(NCC2CCOCC2)C([N+]([O-])=O)=C1)(=O)=O)(=O)C1=CC=C(N2CCN(CC3CCC(C)(C)CC=3C3=CC=C(Cl)C=C3)CC2)C=C1OC1=CN=C2NC=CC2=C1
Sicherheit
  • Risiko- und Sicherheitserkl?rung
  • Gefahreninformationscode (GHS)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Achtung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H361 Kann vermutlich die Fruchtbarkeit beeintr?chtigen oder das Kind im Mutterleib sch?digen. Reproduktionstoxizit?t Kategorie 2 Warnung P201, P202, P281, P308+P313, P405,P501
H372 Sch?digt bei Hautkontakt und Verschlucken die Organe bei l?ngerer oder wiederholter Exposition. Spezifische Zielorgan-Toxizit?t (wiederholte Exposition) Kategorie 1 Achtung GHS hazard pictogramssrc="/GHS08.jpg" width="20" height="20" /> P260, P264, P270, P314, P501
Sicherheit
P201 Vor Gebrauch besondere Anweisungen einholen.
P202 Vor Gebrauch alle Sicherheitshinweise lesen und verstehen.
P260 Dampf/Aerosol/Nebel nicht einatmen.
P264 Nach Gebrauch gründlich waschen.
P264 Nach Gebrauch gründlich waschen.
P270 Bei Gebrauch nicht essen, trinken oder rauchen.
P281 Vorgeschriebene pers?nliche Schutzausrüstung verwenden.
P308+P313 BEI Exposition oder falls betroffen: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen.
P314 Bei Unwohlsein ?rztlichen Rat einholen / ?rztliche Hilfe hinzuziehen.
P405 Unter Verschluss aufbewahren.
P501 Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

ABT-199 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Venetoclax, codeveloped by AbbVie (previously Abbott Laboratories) and Genentech/ Roche, was approved in the US for treatment of patients with chronic lymphocytic leukemia (CLL). To meet qualifications for venetoclax treatment, patients must have received prior therapy and possess the 17p deletion genetic mutation, as determined by USFDA testing. Venetoclax functions as a selective inhibitor of B cell lymphoma subtype 2 (BCL-2), which is often overexpressed on malignant cells and thus leads to impairment of the apoptotic pathway. Along these lines, the orally dosed small molecule drug restores the ability of malignant cells to undergo apoptosis as its mechanism of action.90 Although other BCL-2 inhibitors are known, development of similar agents such as navitoclox have been pursued and halted due to undesired inhibition of BCL-XL, leading to significant thrombocytopenia and demonstrating the need for more selective inhibitors. Venetoclax is also currently being considered for approval in Europe and Canada for similar indications and is in various stages of development for the treatment of non-Hodgkin lymphomas (NHL), acute myeloid leukemia (AML), multiple myeloma (MM), and several other disorders, either as a combination therapy or a stand-alone treatment.

Definition

ChEBI: A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.

ABT-199 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


ABT-199 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 462)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
AFINE CHEMICALS LIMITED
+86-0571-85134551
sales@afinechem.com China 15352 58
Senova Technology Co. Ltd.
+86-0755-86703119 +8618503098836
info@senovatech.com China 351 58
Beijing Mesochem Technology Co.,Ltd
+8613651027935
rachel@mesochem.com China 191 58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
+86-18600796368 +86-18600796368
sales@sjar-tech.com China 456 58
Hebei Mojin Biotechnology Co., Ltd
+86 13288715578 +8613288715578
sales@hbmojin.com China 12834 58
Dorne Chemical Technology co. LTD
+86-86-13583358881 +8618560316533
Ethan@dornechem.com China 3096 58
shandong perfect biotechnology co.ltd
+86-53169958659 +86-13153181156
sales@sdperfect.com China 294 58
Hangzhou ICH Biofarm Co., Ltd
+86-0571-28186870; +undefined8613073685410
sales@ichemie.com China 1001 58
Shandong Hanjiang Chemical Co., Ltd
+86-0533-2066820 +8618369939125
hanson@sdhanjiang.com China 998 58
Shaanxi TNJONE Pharmaceutical Co., Ltd
+8618092446649
sarah@tnjone.com China 1143 58

  • ABT-199
  • ABT-199 (GDC-0199);GDC-0199
  • ABT-199 100MG
  • 2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)met
  • ABT-199, Venetoclax
  • GDC 0199
  • GDC0199
  • Benzamide, 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-
  • ABT 199 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide
  • 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide
  • 2-((1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide
  • Venetoclax (ABT-199)
  • 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]
  • ABT199,GDC0199
  • ABT-199, >=98%
  • 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1 -yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (Venetoclax)(ABT199)
  • Venclexta(abt199)
  • ABT-199, Venetoclax, GDC-0199
  • ABT-199 (GDC-0199)Venetoclax
  • ABT199; GDC0199;ABT 199;GDC 0199;GDC-0199
  • CS-679
  • 105148
  • ABT199;GDC0199;ABT 199;GDC 0199;GDC-0199;VENETOCLAX
  • D00PBX
  • rg7601
  • S8048
  • W-6008
  • X3609
  • Z-3166
  • 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
  • 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (Venetoclax)
  • 99%) (Venetoclax)
  • ABT 199 (>
  • ABT-199 USP/EP/BP
  • Venetoclax trifluoroacetate salt
  • ABT 199 (>99%) (Venetoclax)
  • 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-e n-1-yl]methyl}piperazin-1-yl)-N-(3-nitro-4-{[(oxan-4 -yl)methyl]amino}benzenesulfonyl)-2-{1H-pyrrolo[ 2,3-b]pyridin-5-yloxy}benzamide
  • 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohexy-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsuflonyl)benzamide
  • Venetoclax 95%
  • 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide
  • 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide ABT-199 (GDC-0199)
  • Venetoclax
  • 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]ami
  • Venclexta
  • ATB199
  • Venetoclax (ABT-199, GDC-0199)
  • 2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy
  • D torah
  • GDC-0199
  • BT-199
  • bioavailable,orally,Venetoclax,inhibit,Inhibitor,Bcl-2 Family,GDC0199,GDC 0199,Autophagy
  • Venetoclax ABT199 ABT-199
  • 2-((1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide
  • Venetola
  • Vinetola
  • 1257044-40-8
  • 257044-40-8
  • C45H50ClN7O7S
Copyright 2019 ? ChemicalBook. All rights reserved